Company Overview and News
Let's cut to the chase. It's time to sell a raft of Crown-owned assets like national grid operator Transpower, NZ Post, Pāmu (formerly Landcorp), and more, to reinvest proceeds in developing New Zealand's next generation infrastructure.
C6L AIR MRP MGHTF SINGY ANZFY PGW AIZ PGWFY GNE MYT ANZLY ANZFF GNE PGWFF MEZ GEL SINGF
New Zealand shares bounced back from some of yesterday's sell-off as investors are yet to see serious contagion from Turkey's burgeoning financial crisis, led higher by Synlait Milk and A2 Milk Co. Summerset Group Holdings fell after reporting first-half earnings.
AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ SKT SYKWF SKKTY SNZ SML AIA FBU SPKKY NZTCY SPK FRCEF PGW KWIPF PGWFY AIA FBU ANZLY ANZFF PGWFF MEZ PFGTF
2018-08-06 nzherald.co.nz - 1
PGG Wrightson has agreed to sell its seed and grain business to Danish cooperative DLF Seeds for $421 million in cash and $18 of debt repayment, and signalled it may return up to $292 million to its shareholders.
PGWFF PGW PGWFY
IHC Calf and Rural Scheme has been cancelled for the first time in 33 years due to the risk of spreading the Mycoplasma bovis disease. The long-standing fundraising programme generates more than $1 million annually for people with intellectual disabilities. IHC national manager fundraising Greg Millar said IHC would not be picking up calves or organising calf sales this year. Millar said despite significant improvements in systems, the risk remained too high.
PGWFF PGW PGWFY
In the past few decades, we've seen social media disrupt the news industry, electric technology disrupt the automotive industry and online market places disrupt the retail industry.
SHVTF SHV PGWFF PGW PGWFY
New Zealand shares fell as investors weighed up the impact of Fletcher Building's deeply discounted rights issue soaking up demand from the broader market. Auckland International Airport and exporters A2 Milk Co and Comvita dropped.
CEN FCREY ZNRGF NZTCF RYM ACKDF AUKNY COENF ZNZ GNE ALF CEN SNZ GEL AIA FBU RTBRF SCY RHCGF SPKKY NZTCY SPK ZEL FRCEF PGW COENY PGWFY RTRBY AIA FBU RYHTY RBD GNE PGWFF MEZ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET